Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus

Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus

Tirzepatide, a dual GIP and GLP-1 receptor agonist, is an innovative therapy for type 2 diabetes mellitus (T2DM) and obesity. By stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and enhancing satiety, it offers superior glycemic control and weight reduction compa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Princy Domnic Dsouza, Sai Phalguna Prakash Chitralu, Ramish Khan, Sanatkumar Bharamu Nyamagoud
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-01-01
Series:	MGM Journal of Medical Sciences
Subjects:	glucagon-like peptide-1 (glp-1) glucose-dependent insulinotropic polypeptide (gip) non-alcoholic fatty liver disease (nafld) obesity pharmacodynamics pharmacokinetics polycystic ovarian syndrome (pcos) tirzepatide type 2 diabetes mellitus (t2dm)
Online Access:	https://doi.org/10.4103/mgmj.mgmj_386_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tirzepatide - role in obesity, health and physical wellness. Information overview
by: Anna Hanslik, et al.
Published: (2025-02-01)

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
by: Mark L. Hartman, et al.
Published: (2025-08-01)

Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review.
by: Izabela Stawicka, et al.
Published: (2024-11-01)

The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug
by: I. A. Lugovik, et al.
Published: (2025-06-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

The role of GIPR in food intake control
by: Paula-Peace James-Okoro, et al.
Published: (2025-03-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Physiology and clinical applications of GIP
by: Shunsuke Yamane, et al.
Published: (2025-07-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

Efficacy and Safety of Tirzepatide in the Treatment of Obesity in Adults: A Comprehensive Review
by: Karolina Skonieczna, et al.
Published: (2025-05-01)

Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01)

The evolution of the therapeutic concept ‘GIP receptor antagonism’
by: Frederikke Koefoed-Hansen, et al.
Published: (2025-05-01)

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
by: Yuki Oe, et al.
Published: (2025-05-01)

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
by: Mohammad Amin Karimi, et al.
Published: (2025-05-01)

Effect of high intakes of protein-only and carbohydrate-only on plasma metabolites and hormones, in addition to nitrogen excretion
by: Matthieu Clauss, et al.
Published: (2025-08-01)

The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
by: Bashaier Al-Zaid, et al.
Published: (2025-03-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Gut Hormones and Inflammatory Bowel Disease
by: Jonathan Weng, et al.
Published: (2025-07-01)

Rhabdomyolysis associated with the use of tirzepatide
by: Kunal Sonavane, et al.
Published: (2025-04-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Tirzepatide-induced lichen planus pigmentosus
by: Craig M. Fisher, MD, et al.
Published: (2025-05-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Case Report: Rhabdomyolysis following initiation of tirzepatide
by: Jonas Michael Bodanowitz, et al.
Published: (2025-08-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ligang Liu, et al.
Published: (2025-04-01)

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01)

Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
by: David Vogrinc, et al.
Published: (2024-10-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Corticosteroid Administration Enhances the Glycemic, Insulinemic, and Incretin Responses to a High‐Protein Mixed Meal in Adult Horses
by: Allison T. Palmer, et al.
Published: (2025-03-01)

PANCREATIC AND EXTRA-PANCREATIC EFFECTS OF INCRETINS AND PERSPECTIVES FOR STUDYING ENTEROINSULIN HORMONAL SYSTEM DURING GESTATIONAL DISORDER OF CARBOHYDRATE METABOLISM
by: T. V. Saprina, et al.
Published: (2013-06-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes
by: Elena Vital'evna Kirienkova, et al.
Published: (2015-12-01)

Editorial: Insights in obesity: 2023
by: Katsunori Nonogaki
Published: (2024-11-01)

Glucose-dependent insulinotropic polypeptide (GIP)
by: Timo D. Müller, et al.
Published: (2025-05-01)

Does Incretin Agonism Have Sustainable Efficacy?
by: Sok-Ja Janket, et al.
Published: (2024-11-01)

Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
by: Kexin Zhang, et al.
Published: (2025-08-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)